Stock Details
4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 4,255.29¥. Average daily volumn in 3 months 2.36M. Market cap 6.72T



Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 4,088.00¥. Total volume : 1.74M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)
Last Price
4,088.00¥
Change
68.00
Volume
1.74M

Previous Close4,020.00
Open4,076.00
Day Range4,044.00-4,105.00
Bid4,087.00 x N/A
Ask4,090.00 x N/A
Volume1.74M
Average Volume2.36M
Market Cap6.72T
Beta0.64
52 Week Range3,898.00-6,435.00
Trailing P/E29.17
Foward P/E20.08
Dividend (Yield %)1.49%
Ex-Dividend Date2021-12-29



Financial Details


According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2020 were 786.95B an increase( +14.58%) over the years 2019 revenue that were of 686.18B. In 2020 the company's total earnings were 214.73B while total earnings in 2019 were 157.56B( +36.31%).


Loading ...



Organization

The Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.

Chugai Pharmaceutical Co., Ltd._logo

Market Cap:
6.72T
Revenue:
786.95B
Total Assets:
1.24T
Total Cash:
212.33B


News about "Chugai Pharmaceutical Co., Ltd."

Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and ...

Source from : NIKKEI - 12 days ago


Chugai's ACTEMRA®/RoACTEMRA® Receives Breakthrough Therapy Designation from US FDA for Giant Cell Arteritis

-- The Fifth Breakthrough Therapy Designation Granted for a Chugai Originated Drug -- Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the US Food and Drug Administration (FDA) has ...

Source from : ADVFN - 9 days ago


BRIEF-Japanese Health Ministry Says It Has Given Fast-Track Approval For Chugai Pharmaceutical's Treatment For Covid-19

* JAPANESE HEALTH MINISTRY SAYS IT HAS GIVEN FAST-TRACK APPROVAL FOR CHUGAI PHARMACEUTICAL'S TREATMENT FOR COVID-19 Source text for Eikon: Further company coverage: ...

Source from : Thomson Reuters Foundation - 14 days ago


Chugai Pharma gets Japanese approval for anti-SARS-CoV-2 monoclonal antibody Ronapreve for Intravenous Infusion Set 300 and Set 1332

Chugai Pharmaceutical Co., Ltd. announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-SARS-CoV-2 monoclonal antibody Ronapreve for ...

Source from : Pharmabiz - 13 days ago


Chugai’s Enspryng (Satralizumab) Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Enspryng is a new treatment approved for both adults and adolescents with AQP4-IgG seropositive NMOSD in the EU. It is the first treatment approved in the EU for adolescents from 12 years of age ...

Source from : Business Wire - 1 month ago


Chronolife and Chugai Pharma France to Develop a Smart Textile for the Monitoring of Joint Pathologies

Founded in 1925 in Tokyo, Chugai Pharmaceutical Co., Ltd is one of Japan's leading biotechnology drug development and production laboratories. Mission and Innovation Chugai's slogan is ...

Source from : Benzinga.com - 1 month ago


Japan pharma ramp up push for Covid drug development

Chugai Pharmaceutical Co filed for the drug’s approval with ... although they have yet to reach the clinical trial stage. Shionogi & Co Ltd has been focusing its efforts on commercialising a drug that ...

Source from : The Phnom Penh Post - 21 days ago


New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A

Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. It is marketed in the United States by Genentech as Hemlibra (emicizumab-kxwh ...

Source from : PharmiWeb - 14 days ago


Chugai Pharmaceutical Co Ltd 4519

Narrow moat Chugai’s reported second-quarter earnings that were in line with our expectations. Top-line revenue was JPY 221 billion, or 17% higher than the same period last year, mostly due to ...

Source from : Morningstar%2c Inc. - 5 days ago


CHUGAI PHARMACEUTICAL CO. LTD.R (CUP.SG)

Stocks open higher: S&P 500 sets fresh record high, Dow gains as Nike shares surge after earnings ...

Source from : Yahoo Finance - 25 days ago


Chronolife and Chugai Pharma France to Develop a Smart Textile for the Monitoring of Joint Pathologies

Chronolife, MedTech and service operator for the diagnosis and monitoring of chronic diseases, and the Chugai Pharma France laboratory announce a collaboration to develop a smart textile that will ...

Source from : The Register-Herald - 1 month ago


Chugai Pharmaceutical Co. Ltd.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Source from : Barron's - 3 days ago


Chugai Pharmaceutical Co Ltd

Aug 22 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER FROM JAPAN'S MHLW ...

Source from : Reuters - 1 year ago


Chugai Pharmaceutical Co Ltd CUP

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Source from : Morningstar%2c Inc. - 5 days ago


Chugai Pharmaceutical Co Ltd

Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals products. The Company develops drugs in the fields of cancer, infectious diseases, bone, blood, and circulatory systems.

Source from : Bloomberg - 20 days ago


Chugai Pharmaceutical Co. Ltd.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Source from : Wall Street Journal - 1 year ago


Chugai Pharmaceutical Co Ltd ADR (CHGCY)

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Source from : Nasdaq - 2 month ago


Chugai Pharmaceutical Co. Ltd.

No news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the ...

Source from : Wall Street Journal - 1 month ago


Chugai Pharmaceutical Co Ltd ADR (CHGCY)

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

Source from : Nasdaq - 11 month ago


Chugai Pharmaceutical Co., Ltd. (4519.T)

Private payrolls increased by 978,000 in May, beating expectations: ADP ...

Source from : Yahoo Finance - 1 month ago


U.S. Warns on U.K. Travel; Australia Lockdowns: Virus Update

Roche Holding AG and Chugai Pharmaceutical Co.’s Ronapreve was cleared as an ... Senior officials from Nippon Telegraph & Telephone Corp., Fujitsu Ltd. and NEC Corp. will skip the event given ...

Source from : MSN - 13 days ago


Global Hemophilia A Treatment Market

Chugai Pharmaceutical Co. Ltd., Novo Nordisk A/S., and Octapharma AG among others global and domestic players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC ...

Source from : openpr.com - 4 days ago


Lateral Epicondylitis (Tennis Elbow) Disease

Disease Market size is projected to make from USD xx in 2021 to USD xx by 2027, at a Compound Annual Growth Rate (CAGR) of xx during the gauge time frame. The global Lateral Epicondylitis (Tennis ...

Source from : manometcurrent.com - 11 days ago


Chronolife and Chugai Pharma France to Develop a Smart Textile for the Monitoring of Joint Pathologies

PARIS, June 28, 2021--(BUSINESS WIRE)--Chronolife, MedTech and service operator for the diagnosis and monitoring of chronic diseases, and the Chugai Pharma France laboratory announce a collaboration ...

Source from : Yahoo Finance - 1 month ago


Joint Pain Injections Market is expected to reach around US$ 5.7 billion by 2026: Covering Covid-19 Analysis

The global Joint Pain Injections market is expected to grow at noteworthy CAGR around 8 % throughout the forecast period and reach around US$ 5.7 billion by 2026. The report provides analysis of ...

Source from : Medgadget - 4 days ago


Histology of Symptomatic Gastroesophageal Reflux Disease

Background and Aim: To examine the differences in esophageal histopathology between non-erosive reflux disease (NERD) and reflux esophagitis (RE), and to investigate whether baseline esophageal ...

Source from : Medscape - 4 days ago


Drug developers above water, but some index members struggle

“The MHLW approval is significant because it is Regen-Cov’s first full approval globally, as well as the first in Japan for a mild to moderate COVID-19 treatment,” Tomoko Shimizu, spokeswoman at ...

Source from : BioWorld - 12 days ago


New data for Roche's Hemlibra reinforce safety profile in people with haemophilia A

Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. It is marketed in the United States by Genentech as Hemlibra (emicizumab ...

Source from : Benzinga.com - 14 days ago


Histology of Symptomatic Gastroesophageal Reflux Disease

Papillary extension (Length of papilla)/(thickness of whole epithelium) × 100 = % Basal cell hyperplasia (Thickness of basal cell layer)/(thickness of whole epithelium) × 100 = % Ki-67 ...

Source from : Medscape - 9 days ago


Press Release: New data for Roche's Hemlibra reinforce safety profile in people with haemophilia A_image

Press Release: New data for Roche's Hemlibra reinforce safety profile in people with haemophilia A

Final analysis from the phase IIIb STASEY study, including data from 193 people with haemophilia A, further support the benefit/risk profile of ...

Source from : Finanztreff - 14 days ago


Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt

that we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the VS-6766 license agreement; that we may not have sufficient cash to fund our contemplated operations; that we may be ...

Source from : PharmiWeb - 14 days ago


FOCUS: Toshiba management woes seen deepening after strong shareholder rebuke

a former outside director at Sony Corp. and currently honorary chairman of Chugai Pharmaceutical Co., were part of its efforts. The shareholder revolt, led by foreign activist investors ...

Source from : MSN - 1 month ago


New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A

Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. Hemlibra U.S. Indication Hemlibra is a prescription medicine used for ...

Source from : The Register-Herald - 14 days ago


F. Hoffmann-La Roche Ltd: New data for Roche's Hemlibra reinforce safety profile in people with haemophilia A

Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. It is marketed in the United States by Genentech as Hemlibra (emicizumab ...

Source from : Finanznachrichten - 14 days ago


New Data for Genentech's Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A

Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. Hemlibra U.S. Indication Hemlibra is a prescription medicine used for routine ...

Source from : Stockhouse - 14 days ago


Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care

Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. It is marketed in the United States by Genentech as Hemlibra (emicizumab-kxwh ...

Source from : Yahoo News - 1 month ago


Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors

that we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the VS-6766 license agreement; that we may not have sufficient cash to fund our contemplated operations; that we may be ...

Source from : MarketWatch - 1 month ago


New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A

Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. It is marketed in the United States by Genentech as Hemlibra (emicizumab ...

Source from : wallstreet online - 14 days ago